Home / Research / CJC-1295 + ipamorelin teardown

Paper-trail teardown · FDA reviews and votes, a patent, company releases, trial registries, the tesamorelin label and original papers read · Sources checked October 17, 2026

Does the CJC-1295 and ipamorelin stack work? Nobody has tested it in people, and FDA’s advisers voted against both halves.

CJC-1295 and ipamorelin are sold together as a growth hormone stack for sleep, fat loss and recovery. The idea has a real basis: drugs that hit these two receptors at once released far more growth hormone in a 1993 test than either alone.[29] But no published trial has given this pair to people.[1][2][34][35] The “CJC-1295” in most stacks, the version without DAC, has never been given to a person in any published study.[1][34] FDA’s advisers voted against CJC-1295 by 0 to 13 and against ipamorelin by 0 to 12 in 2024.[3][4] The approved drug in this family, tesamorelin (Egrifta), shows what the approach can do and what it costs.[24]

Why this matters this week

On October 14, 2026 FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House for review. The listing names no peptides, the text isn’t public, and the review was still open when we checked on October 17.[6] A meeting about it is booked with White House reviewers for October 21 at 3 PM, requested by the American Academy of Peptide Medicine. The requestor listed is Lee Rosebush,[7] who also spoke at FDA’s public hearings on ipamorelin and CJC-1295 in 2024.[3][4]

What hasn’t been reported is where these two drugs stand. FDA’s advisers already rejected both in 2024. Neither is on the agenda of the July 2026 meeting or the one due by February 2027.[3][4][8] Ipamorelin is still on FDA’s list of compounding substances with significant safety risks for outsourcing facilities.[5] Meanwhile we counted 682 posts on X mentioning tesamorelin, ipamorelin or CJC-1295 in the seven days to October 17, rising from 85 on October 11 to 134 on October 16. They come with doses and promises: “250mcg/250mcg nightly,” “the pair outruns either one alone,” “Legal nationwide access to compounded peptides is here.”[36] So we traced both drugs back to their first papers.

Two drugs, two switches

Growth hormone release from the pituitary has two main “go” signals. One is GHRH, a hormone from the brain. The other is ghrelin, a gut hormone that also acts on the pituitary. CJC-1295 is a lab-made copy of the active first 29 amino acids of GHRH, with four of them swapped to make it last longer.[1][14] Ipamorelin is a five-amino-acid peptide that Novo Nordisk built in the 1990s to work on the ghrelin receptor.[20] Its selling point in animals was selectivity. In pigs it released growth hormone without raising the stress hormones ACTH and cortisol, “even at doses more than 200-fold higher” than the dose that worked.[20]

Pairing the two signals isn’t a gym myth. In a 1993 study in Spain, groups of people with obesity got a single IV dose of GHRH, of GHRP-6 (an older cousin of ipamorelin), or both. Peak growth hormone averaged 6.8 µg/L after GHRH, 15.7 after GHRP-6, and 42.2 after both together.[29] That is a real strength of the stack’s logic. It was a one-time spike with different molecules, though, not CJC-1295 and ipamorelin, and a bigger hormone spike isn’t the same thing as better sleep or less fat.

“CJC-1295” is two different drugs

The CJC-1295 that was tested in people carries an extra chemical hook called DAC (drug affinity complex). After injection it latches onto albumin, the most common protein in blood, and that stretches its half-life in people to 5.8 to 8.1 days.[10][13] The version in most of the stack posts we read is CJC-1295 without DAC, also sold as “Mod GRF 1-29.” It is the same 29 amino acids without the hook.[1][36] FDA counted at least five different substances under the CJC-1295 name and warned that the “inconsistent naming conventions” are themselves a safety risk.[1]

FDA’s 2024 review found no study establishing whether CJC-1295 without DAC is even pharmacologically active.[1] It called a 2010 report the first mention of it in the scientific literature: a Norwegian anti-doping lab identified it in an unknown preparation that police and customs had sent for testing in 2009.[1][19] But there is an older record. ConjuChem, the Montreal company that invented CJC-1295, made the no-DAC peptide in its 2002 patent application, as the plain comparison for the DAC version. The patent’s figures show it releasing growth hormone from rat pituitary cells and in rats. In rat blood, though, it “disappears very rapidly” and “could not be detected after 60 minutes,” whether injected under the skin or into a vein. The DAC version was still detectable at 96 hours.[14] That rat comparison is the only measurement of the no-DAC peptide in a living body that we found. Nobody has published a study giving it to a person.[34][35]

What happened when CJC-1295 was given to people

ConjuChem tested the DAC version in healthy adults aged 21 to 61. A single injection raised growth hormone 2 to 10 times for at least six days and IGF-1, the hormone growth hormone drives, 1.5 to 3 times for 9 to 11 days.[10] A second team found the body’s normal growth hormone pulses kept going on top of the raised baseline, with IGF-1 up 45% in 12 young men.[11] So the drug did what it was designed to do.

Side effects were common. In the first ConjuChem trial, 33 of 35 people on the drug reported an adverse event, against 2 of 7 on placebo. About 70% had injection-site reactions, 63% had headaches (14% on placebo), 43% had diarrhea, and 30% had “systemic vasodilatory reactions”: flushing, warmth and brief drops in blood pressure. In the second trial, flushing hit 40% of people at the low dose and all of them at the high dose. One person had brief involuntary leg contractions and some loss of coordination.[1] In all, FDA counted 63 healthy adults in the published studies. 87% were men, and 73% got a single injection. FDA found no study in which any form of CJC-1295 was given to people with a disease.[1][12]

The one trial in patients didn’t finish. ConjuChem enrolled 192 people with HIV-related fat changes and gave weekly injections planned for 12 weeks. On July 13, 2006, a patient in Argentina got his 11th weekly dose. About two hours later he had chest discomfort, an ECG confirmed a heart attack, and he died about an hour after that.[16] The company stopped dosing the next day.[15] The trial doctor thought the most likely cause was undiagnosed heart disease and that the death was unrelated to the drug.[1] The program never resumed, no results were ever posted or published,[1][17] and ConjuChem went bankrupt in 2010.[18]

Ipamorelin’s record in people

Two companies gave ipamorelin to people, and both did it by vein. In 1999 Novo Nordisk infused five dose levels into healthy men, six men per dose. It cleared with a half-life of about two hours. Growth hormone spiked once, peaking at about 40 minutes, and was back to very low levels by six hours.[21][2] FDA’s summary notes the lowest dose produced growth hormone levels too small to include in the analysis.[2]

The drugmaker Helsinn then tried it for the gut paralysis that can follow bowel surgery. In a trial of 114 patients, ipamorelin at 0.03 mg/kg twice daily by vein didn’t beat placebo: median time to a first tolerated meal was 25.3 hours versus 32.6, a difference that wasn’t statistically significant (p = 0.15).[22] FDA’s review lists more low potassium (12.5% versus 3.4%) and high blood sugar at discharge (14.3% versus 8.6%) on ipamorelin. Two patients on ipamorelin died after leaks at the site where their bowel was rejoined. FDA says it is unclear whether ipamorelin played a role,[2] and that study is the “death” in FDA’s safety listing.[5]

Then Helsinn ran a bigger trial. The registry shows 320 patients randomized to three ipamorelin doses, up to 0.06 mg/kg three times a day, or placebo. It finished in May 2014. No results were posted, and we found no paper.[23][34] FDA says development was discontinued.[2] FDA also found no human data at all for ipamorelin injected under the skin, which is how it is sold.[2]

What we found when we did the math on doses

A common X dose is 250 to 300 mcg of ipamorelin under the skin at night, often with the same amount of CJC-1295 without DAC.[36] For a 70 to 80 kg adult, that’s about 3 to 4 mcg per kg. Novo’s lowest IV dose, 4.21 nmol/kg, works out to about 3 mcg per kg, or 0.21 mg for a 70 kg man, using ipamorelin’s molecular weight of 711.85.[2][21] That is the dose group FDA says produced growth hormone levels too low to analyze.[2] Helsinn’s failed surgery trial used 0.03 mg/kg (2.1 mg for a 70 kg adult), about seven to eight times the X dose, by vein, twice a day.[22]

This is our arithmetic, and it has limits. An injection under the skin is absorbed differently from an IV drip, the Novo study was in healthy young men, and nobody has measured what an under-the-skin dose does in people.[2] The point is narrower: the doses on X sit at the bottom of the only human dose range ever tested, and they were never tested by the route people use.

FDA’s advisers already voted on both

On October 29, 2024, FDA asked its compounding advisers whether ipamorelin should go on the list of substances regular pharmacies may use. FDA reviewed it for growth hormone deficiency and post-surgery gut paralysis. Both forms lost 0 to 12, with 1 abstention. Members who voted no cited “a lack of information supporting safety and efficacy.” One added that “the high frequency of a drug being prescribed does not necessarily mean the drug is safe and effective.”[4]

On December 4, 2024, the same committee voted on five forms of CJC-1295, with and without DAC, for growth hormone deficiency. Four lost 0 to 13 and one lost 1 to 12.[3] AOD-9604 and thymosin alpha-1 were rejected at the same meeting.[3] An April 2026 law-firm analysis points to that history as precedent: peptides that came off FDA’s risk list after their nominations were withdrawn were then reviewed, and the committee recommended against each.[9]

In April 2026 FDA took 12 other peptides off that risk list and scheduled them for new meetings in July 2026 and by February 2027. CJC-1295 and ipamorelin aren’t on either agenda.[8][9] Ipamorelin is still listed as a significant safety risk for outsourcing facilities.[5] Committee votes are advice, not law, and the agency can depart from them.[9] Whether the policy now at the White House covers these two drugs is unknown, because its text isn’t public.[6]

Tesamorelin: what an approved version shows

Tesamorelin is also a lab-made GHRH, built on the hormone’s full 44 amino acids, and FDA approved it as Egrifta on November 10, 2010.[25][27] Unlike CJC-1295 and ipamorelin, it has large randomized trials behind it. In two 26-week trials in 816 people with HIV and excess belly fat, a daily 2 mg injection cut deep belly (visceral) fat by 15.2% versus a 5.0% rise on placebo in the first trial, and by 10.9% versus 0.6% on placebo in the second.[26][27] That is the “approval data” people cite on X, and it’s real.[36][24] It is approved only for that use. The label says it is “not indicated for weight loss management as it has a weight neutral effect.”[24]

The same label lists the costs, which apply to the whole idea of pushing this system. People who stopped lost the benefit: in the two trials, visceral fat rose 22% and 16% over the next 26 weeks in patients switched to placebo.[24][27] New diabetes-range blood sugar (HbA1c of 6.5% or more) showed up in 5% versus 1% on placebo. Nearly half of patients (47%) had IGF-1 levels more than two standard deviations above normal by 26 weeks, and the label says “the effects of prolonged elevations in IGF-1 levels are unknown.” Fluid retention, joint pain and carpal tunnel syndrome are listed warnings.[24] Half of patients made antibodies to tesamorelin. In about 60% of those, the antibodies also reacted with the body’s own GHRH, and by week 52 some patients had antibodies that blocked tesamorelin (10%) or natural GHRH (5%) in lab tests.[24] FDA raised that same risk for CJC-1295, which shares 86% of its sequence with natural GHRH.[1] Tesamorelin’s label shows it isn’t hypothetical for this class.

The longevity question

Growth hormone falls with age, and restoring it is the pitch behind many of these stacks. The most direct test of the idea is giving growth hormone itself to healthy older people. A 2007 review pooled 18 trials with 220 people on growth hormone. They lost 2.1 kg of fat and gained 2.1 kg of lean mass with no change in weight, and they had more swelling, joint pain, carpal tunnel syndrome and breast growth in men, plus a little more diabetes. The authors concluded that growth hormone “cannot be recommended as an antiaging therapy.”[30]

The best evidence in this family for older people comes from tesamorelin, not CJC-1295. In a 20-week University of Washington trial, 152 adults aged 55 to 87 injected 1 mg nightly. Executive function scores improved versus placebo, body fat fell 7.4%, and IGF-1 rose 117% but stayed within the normal range. Fasting insulin rose 35% in those with mild memory problems, and 68% reported side effects versus 36% on placebo.[28] It was promising and short, and it hasn’t been repeated at scale.

The other side of the ledger: people in Ecuador born unable to respond to growth hormone had almost no cancer or diabetes over 22 years of follow-up.[31] Dwarf mice that make very little growth hormone outlive their normal littermates.[33] Among 184 people in their 90s, women with lower IGF-1 lived longer.[32] None of this proves that raising growth hormone shortens life. It does mean more growth hormone and IGF-1 is not a settled longevity lever, and nobody has tested whether this stack helps or harms people as they age.

Checking the claims going around this week

“The pair outruns either one alone.” For a single growth hormone spike, with older drugs of the same two types, yes.[29] For CJC-1295 with ipamorelin, nobody has measured it in people, and nobody has tested whether a bigger spike changes sleep, fat or recovery.[1][2][34]

“No DAC clears in about 30 minutes… 100mcg SubQ, 2–3x daily… deeper sleep the first week.” There is no human measurement of how fast it clears, no tested dose and no sleep study. The only data on how long it lasts come from rats, in which it was undetectable within an hour.[1][14][36]

“A quick flush after the pin is normal.” Flushing was common in the CJC-1295 trials: up to all participants at the high dose, sometimes with drops in blood pressure.[1] FDA lists “systemic vasodilatory reaction” among the serious adverse events it found for CJC-1295.[5] Common isn’t the same as harmless.

“Tesamorelin has approval data behind it” and “can nudge blood sugar up.” Both true. The approval covers belly fat in HIV lipodystrophy, not weight loss, and the label reports new diabetes-range blood sugar in 5% versus 1%.[24][36]

“Legal nationwide access to compounded peptides is here.” Not as of October 17. The policy hasn’t cleared White House review, its list of peptides isn’t public, and ipamorelin is still on FDA’s safety-risk list for outsourcing facilities.[6][5]

Safety: what isn’t known

No one has run the two-year cancer studies for any form of CJC-1295. Mice engineered to overproduce GHRH develop enlarged pituitaries and pituitary tumors, which is why FDA flagged the gap.[1] In a mouse study, eight weeks of CJC-1295 with DAC enlarged the pituitary and caused DNA damage in pituitary cells.[1] Animal studies found bleeding, inflammation and tissue death at injection sites.[1] FDA’s adverse event database had almost nothing on either drug: two unusable reports for CJC-1295 through June 2024 and two non-serious reports for ipamorelin through September 2023.[1][2] That reflects how little these drugs reach formal reporting, not proof of safety. The only outsourcing facility that reported making CJC-1295 made it premixed with ipamorelin in 2019 and 2020, and none has reported it since.[1]

Bottom line

The logic of the stack is sound biology: two separate signals for growth hormone, which together produced a bigger spike in older studies.[29] CJC-1295 with DAC reliably raised growth hormone and IGF-1 in healthy adults, and tesamorelin proved a GHRH drug can shrink visceral fat in a large trial.[10][26] Everything past that is untested. The no-DAC CJC-1295 in most stacks has never been studied in a person. Ipamorelin was only ever tested by vein, and its larger trial was never reported. The pair has never been tested together. FDA’s advisers rejected both in 2024.[1][2][3][4][23] If the White House clears FDA’s policy, the question of whether pharmacies can sell them may change. Whether they work won’t.

This page analyzes regulatory documents, a patent, company records, trial registries, a drug label and published research. It is not medical advice and does not recommend using, sourcing, or dosing CJC-1295, ipamorelin or tesamorelin. The PubMed and X counts and the dose arithmetic are Jabbit’s own; inputs are cited above.